rapamune, mycophenolate mofetil and steroid + tacrolimus, sirolimus and steroid
Pre-clinicalCompleted 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Absence; Kidney
Conditions
Absence; Kidney
Trial Timeline
Aug 1, 2009 → Jul 1, 2014
NCT ID
NCT01005706About rapamune, mycophenolate mofetil and steroid + tacrolimus, sirolimus and steroid
rapamune, mycophenolate mofetil and steroid + tacrolimus, sirolimus and steroid is a pre-clinical stage product being developed by Pfizer for Absence; Kidney. The current trial status is completed. This product is registered under clinical trial identifier NCT01005706. Target conditions include Absence; Kidney.
What happened to similar drugs?
1 of 4 similar drugs in Absence; Kidney were approved
Approved (1) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01005706 | Pre-clinical | Completed |
Competing Products
9 competing products in Absence; Kidney
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| topiramate | Johnson & Johnson | Phase 2 | 35 |
| Idelalisib | Gilead Sciences | Pre-clinical | 18 |
| Brivaracetam Film-coated tablet + Brivaracetam oral solution | UCB | Phase 3 | 47 |
| Brivaracetam Film-coated tablet + Brivaracetam oral solution | UCB | Phase 3 | 40 |
| Levetiracetam | UCB | Phase 2 | 35 |
| Brivaracetam | UCB | Phase 3 | 44 |
| Sativex and rifampicin + Sativex and rifampicin + Sativex and ketoconazole + Sativex and ketoconazole + Sativex and omeprazole + Sativex and omeprazole | Jazz Pharmaceuticals | Phase 1 | 26 |
| Cannabidiol (Epidiolex) | Jazz Pharmaceuticals | Approved | 40 |
| BMB-101 | Bright Minds Biosciences | Phase 2 | 36 |